Close this search box.

SPOT ME: Serial Pediatric Omics Tracking for ME/CFS

This study seeks to understand pathological mechanisms of pediatric ME/CFS (13 to 18 years old), using case-control and longitudinal study design that meshes clinical measures and omics methods.

  • Christopher Armstrong, PhD
  • Paul Gooley, PhD
  • Adam Scheinberg, MD
  • Sarah Knight, PhD
  • Elisha Josev, PhD
  • Natalie Thomas, PhD
    • IRB/clinical protocol completed and approved.
    • Recruitment has begun at the Royal Children’s Hospital in Melbourne and is ongoing.
    • Exploring incorporation of proteomics.
    • Expanded protocol to include MRI study on the patients.


    Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is diagnosed by its symptoms, which include post-exertional malaise, fatigue, sleep disturbance, pain and cognitive impairment.  Currently, there is no biomarker for diagnosis, and it is unclear how symptoms arise to create this chronic pathological state. Research into potential disease mechanisms in adolescents with ME/CFS is severely limited, despite adolescence representing a major age peak in the incidence of ME/CFS.

    The outcomes of this project are to discover novel metabolic biomarkers in ME/CFS, link metabolism to the fluctuation of symptoms, determine mitochondrial function in ME/CFS, and produce a plethora of new knowledge for the field of ME/CFS.


    Paediatric ME/CFS patients from the Royal Children’s Hospital’s Paediatric ME/CFS Clinic will be invited to participate in our study. We would first collect a blood sample and urine sample in conjunction with a symptom survey, questionnaire, and cognitive assessment. We would then engage consenting participants in a longitudinal study with wearable health technology while collecting urine and blood microsamples from patients over time.

    Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

    What are the advantages of giving from your Donor Advised Fund (DAF)?

    • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
    • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
    • Your fund’s investment gains accumulate tax free.
    • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

    How do I make a donation through my DAF?

    Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

    Still can’t find your fund? 

    • Request a grant distribution through your Donor Advised Fund sponsor
    • Be sure to use OMF’s EIN #26-4712664
    • You can also designate OMF as a beneficiary for your Donor Advised Fund
    • Questions? Give us a call at 650-242-8669